What Does OncoSec Do?

Total employees23
HeadquartersPennington
Founded2011

OncoSec Medical Incorporated was a clinical-stage biotechnology company pioneering the development of novel intratumoral immunotherapies. Their primary focus was on utilizing their proprietary technology to deliver DNA-based therapeutics directly into tumors, aiming to stimulate a patient's own immune system to target and eradicate cancer cells. The company's lead investigational therapy, TAVO™ (tavokinogene telseplasmid), involved the intratumoral delivery of a DNA plasmid encoding for interleukin-12 (IL-12), a potent naturally occurring anti-cancer protein, often combined with their electroporation device, a GENESIS or Apollo system, to enhance cellular uptake. OncoSec concentrated on addressing unmet medical needs in oncology, particularly in difficult-to-treat cancers like metastatic melanoma and triple-negative breast cancer. In early 2024, OncoSec Medical Inc. completed a merger with Adgero Biopharmaceuticals Holdings, Inc., with the combined entity operating as Adgero Biopharmaceuticals Holdings, Inc.

Where Is OncoSec's Headquarters?

HQ Function

Served as the central hub for corporate administration, clinical development oversight, research collaborations, and strategic planning for its immunotherapy programs.

Notable Features:

The facility likely comprised modern office spaces and potentially access to or coordination with lab facilities suitable for a biotechnology company focused on clinical development.

Work Culture:

As a clinical-stage biotech, the work culture was likely dynamic, science-driven, and highly collaborative, with a strong emphasis on innovation, research integrity, and the mission to develop impactful cancer therapies.

HQ Significance:

The Pennington headquarters was critical for managing OncoSec's clinical trials, R&D pipeline progression, investor relations, and regulatory interactions in the US.

Values Reflected in HQ: The headquarters operations aimed to reflect innovation, scientific rigor, patient-centricity, and a commitment to advancing cancer treatment.

Location:

While primarily US-based in its physical operations, OncoSec Medical Inc. had a global reach through its clinical trials conducted at various international sites, collaborations with global research institutions, and presentations at international scientific conferences. Its drug development programs aimed to address cancer, a global health issue.

Street Address:

24 N. Main Street

City:

Pennington

State/Province:

New Jersey

Country:

USA

Where Else Does OncoSec Operate Around the World?

San Diego, California/USA

Address: Not consistently listed post-Pennington focus; previously had a significant presence.

Supported early-stage research, discovery, and potentially some clinical operations in the Western US.

Buying Intent Signals for OncoSec

Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.

Notable news
Hiring actively
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
*Example signal, not calculated in real time

Who's Leading OncoSec? Meet the Executive Team

As of April 2025, OncoSec' leadership includes:

Robert (Bob) H. Arch - President and Chief Executive Officer
Joe O'Boyle - Chief Financial Officer
Dr. George E. Peoples - Chief Medical Officer (Also became CMO of the merged Adgero)
Brian Leuthner - Chief Operating Officer

Who's Investing in OncoSec?

OncoSec has been backed by several prominent investors over the years, including:

China Grand Pharmaceutical and Healthcare Holdings Limited (CGP)
Alpha Capital Anstalt
Public shareholders (formerly traded as ONCS)

What Leadership Changes Has OncoSec Seen Recently?

Hire1
Exits0

The most significant recent executive event was the merger with Adgero Biopharmaceuticals in early 2024, which effectively restructured the leadership. Prior to that, key appointments shaped OncoSec's late-stage clinical development.

New Appointments:

Robert H. Arch, Robert H. Arch was appointed as President and CEO.

What Technology (Tech Stack) Is Used byOncoSec?

Discover the tools OncoSec uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.

OncoSec Email Formats and Examples

OncoSec Medical Inc. likely utilized common corporate email formats, often combining first initial and last name.

[first_initial][last]@oncosec.com

Format

rarch@oncosec.com

Example

70%

Success rate

What's the Latest News About OncoSec?

GlobeNewswireFebruary 7, 2024

OncoSec Medical Incorporated Announces Completion of Merger With Adgero Biopharmaceuticals Holdings, Inc.

OncoSec Medical Incorporated announced the completion of its previously announced merger with Adgero Biopharmaceuticals Holdings, Inc. The combined company will operate under the name Adgero Biopharmaceuticals Holdings, Inc. and its common stock will trade on the Nasdaq Capital Market under the ticker symbol 'ADGE'....more

GlobeNewswireMarch 20, 2023

OncoSec Appoints Robert H. Arch as President and Chief Executive Officer

OncoSec Medical Incorporated announced the appointment of Robert (Bob) H. Arch as President and Chief Executive Officer and a member of the Board of Directors, effective March 20, 2023....more

GlobeNewswireDecember 12, 2022

OncoSec Announces Promising Interim Data from the KEYNOTE-695 Trial in Patients with Anti-PD-1 Checkpoint Refractory Metastatic Melanoma at ESMO IO 2022

OncoSec presented promising interim data from its Phase 2b KEYNOTE-695 trial evaluating TAVO™ in combination with KEYTRUDA® (pembrolizumab) in patients with anti-PD-1 checkpoint refractory metastatic melanoma. The data showed clinically meaningful and durable responses....more

Highperformr's free tools for company research

Explore Employees by Region or Country

See where a company’s workforce is located, by country or region.

View Funding Details

View past and recent funding rounds with amounts and investors.

Understand Revenue Insights

Understand company revenue estimates and financial scale.

Track Active Job Openings

Track active roles and hiring trends to spot growth signals.

Review Product and Offerings

Discover what a company offers—products, platforms, and solutions.

Get SIC or NAICS Codes

Get the company’s official SIC and NAICS classifications.

Analyze Website Traffic Trends

Analyze visitor volume, engagement, and top traffic sources.

Discover Social Profiles and Engagement

Explore LinkedIn, Twitter, and other active social profiles.

Identify Top Competitors

Identify top competitors based on similar business traits.

Research and Discover Companies with Highperformr — Smarter, Faster

Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.

Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.

  • Track intent signals to find buyers who are actively in-market
  • Enrich contacts and companies instantly, no need to switch tools
  • Automate workflows to stay ahead of every change
  • Connect your CRM & tools for seamless data sync and activation

Thousands of companies, including OncoSec, are just a search away.